Regulatory & Reimbursement
FDA Output, April 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in April 2026. Updated April 6.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
Start-Ups
GT Medical: Treating Brain Tumors with Speed and Certainty
An update on a company bringing localized, immediate, and beam-free radiotherapy to brain cancer patients.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
Pathways' Picks
Pathways' Pick of the Week: More WET in Europe
EU expands the “well-established technologies” list subject to simplified rule. Excerpted from Pathways Picks March 25: Deregulation in the US and EU, Digital Health Roundup, and More.